SCHEMBL19486752

SCHEMBL19486752

CC(C)N1CC[C@@H](c2ccc(-c3cc4c(N5CCN(C=O)CC5)ccnn4c3)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BMPR1B O00238 1/20 0.38
BMPR1A P36894 1/20 0.38
TGFBR1 P36897 1/20 0.38
ACVRL1 P37023 1/20 0.38
ACVR1 Q04771 1/20 0.38
PARP1 P09874 3/20 0.37
KIT P10721 4/20 0.35
ESRRG P62508 2/20 0.33
PARP2 Q9UGN5 1/20 0.33
ESRRB O95718 1/20 0.33
ESR1 P03372 1/20 0.33
MC4R P32245 1/20 0.33
KCNH2 Q12809 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
TLR8 Q9NR97 2/20 0.33
TLR7 Q9NYK1 2/20 0.33
TLR9 Q9NR96 1/20 0.33
RET P07949 3/20 0.32
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486330 1.00 BMPR1B (0.38) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19486483 0.95 PARP1 (0.39) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19486842 0.95 PARP1 (0.39) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19486477 0.94 KCNH2 (0.38) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19486399 0.94 KIT (0.37) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19486375 0.86 KIT (0.36) KITHRH3RETDRD3
SCHEMBL19486377 0.86 KIT (0.36) KITHRH3RETDRD3
SCHEMBL19481746 0.85 BMPR1B (0.41) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19481742 0.85 BMPR1B (0.41) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1
SCHEMBL19481756 0.85 BMPR1B (0.41) BMPR1BBMPR1ATGFBR1ACVRL1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 BMPR1B 12/4885BMPR1A 13/4885TGFBR1 43/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 BMPR1B 14/4885BMPR1A 13/4885TGFBR1 19/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 BMPR1B 12/4885BMPR1A 13/4885TGFBR1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.